US2003134283A1PendingUtilityA1
Genes regulated in dendritic cell differentiation
Priority: Oct 3, 2000Filed: Oct 3, 2001Published: Jul 17, 2003
Est. expiryOct 3, 2020(expired)· nominal 20-yr term from priority
C12Q 2600/158C12Q 1/6883
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in dendritic cells, which may be used in their entirety or in part to diagnose, to stage, to treat, or to monitor the treatment of a subject with cancer, infectious disease, autoimmunity, allergy, and graft versus host disease or to enhance a vaccine.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A combination comprising a plurality of cDNAs that are differentially expressed in DC, and selected from SEQ ID NOs:1-260 or their complements.
2 . The combination of claim 1 , wherein each of the cDNAs is downregulated in DC and is selected from SEQ ID NOs:1-29.
3 . The combination of claim 1 , wherein each of the cDNAs is upregulated in DC and is selected from SEQ ID NOs:30-241.
4 . The combination of claim 1 , wherein each of the cDNAs is upregulated in mature DC and is selected from SEQ ID NOs:242-257.
5 . The combination of claim 1 , wherein each of the cDNAs is downregulated in mature DC and is selected from SEQ ID NOs:258-260.
6 . The combination of claim 1 , wherein the cDNAs are immobilized on a substrate.
7 . A high throughput method for detecting differential expression of one or more cDNAs in a sample containing nucleic acids, the method comprising:
(a) hybridizing the substrate of claim 6 with nucleic acids of the sample, thereby forming one or more hybridization complexes; (b) detecting the hybridization complexes; and (c) comparing the hybridization complexes with those of a standard, wherein differences between the standard and sample hybridization complexes indicate differential expression of cDNAs in the sample.
8 . The method of claim 7 , wherein the nucleic acids of the sample are amplified prior to hybridization.
9 . The method of claim 7 , wherein the sample is from a subject with cancer, infectious disease, autoimmunity, allergy, or graft versus host disease and comparison with a standard identifies or stages the disorder.
10 . A high throughput method of screening a plurality of molecules or compounds to identify a ligand which specifically binds a cDNA, the method comprising:
(a) combining the combination of claim 1 with the plurality of molecules or compounds under conditions to allow specific binding; and (b) detecting specific binding between each cDNA and at least one molecule or compound, thereby identifying a ligand that specifically binds to each cDNA.
11 . The method of claim 10 wherein the plurality of molecules or compounds are selected from aptamers, DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and regulatory proteins.
12 . An isolated cDNA selected from the group consisting of SEQ ID NOs:24-29, 187-202, 205-213, 216-241, 256, 257, 259, and 260.
13 . A vector containing the cDNA of claim 12 .
14 . A host cell containing the vector of claim 13 .
15 . A method for producing a protein, the method comprising the steps of:
(a) culturing the host cell of claim 14 under conditions for expression of protein; and (b) recovering the protein from the host cell culture.
16 . A protein or a portion thereof produced by the method of claim 15 .
17 . A high-throughput method for using a protein to screen a plurality of molecules or compounds to identify at least one ligand which specifically binds the protein, the method comprising:
(a) combining the protein of claim 16 with the plurality of molecules or compounds under conditions to allow specific binding; and (b) detecting specific binding between the protein and a molecule or compound, thereby identifying a ligand which specifically binds the protein.
18 . The method of claim 17 wherein the plurality of molecules or compounds is selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, proteins, agonists, antagonists, antibodies or their fragments, immunoglobulins, inhibitors, drug compounds, and pharmaceutical agents.
19 . A method of using a protein to produce an antibody, the method comprising:
a) immunizing an animal with the protein of claim 16 under conditions to elicit an antibody response; b) isolating animal antibodies; and c) screening the isolated antibodies with the protein, thereby identifying an antibody which specifically binds the protein.
20 . A antibody produced by the method of claim 19.Join the waitlist — get patent alerts
Track US2003134283A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.